Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)

[1]  Heikki Joensuu,et al.  Practical management of tyrosine kinase inhibitor-associated side effects in GIST. , 2011, Cancer treatment reviews.

[2]  V. Spataro.  Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  U. Demirci,et al.  Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors , 2010, Medical oncology.

[4]  H. Kantarjian,et al.  Imatinib front‐line therapy is safe and effective in patients with chronic myelogenous leukemia with pre‐existing liver and/or renal dysfunction , 2010, Cancer.

[5]  J. Blay,et al.  Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). , 2010, European journal of cancer.

[6]  C. Antonescu,et al.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[7]  Vivek Roy,et al.  N0338 phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer , 2008 .

[8]  Pingfu Fu,et al.  Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Marciano,et al.  Imatinib-induced fatal acute liver failure. , 2007, World journal of gastroenterology.

[10]  Y. Mun,et al.  Early Imatinib Mesylate-Induced Hepatotoxicity in Chronic Myelogenous Leukaemia , 2007, Acta Haematologica.

[11]  M. Bruguera,et al.  Hepatitis tóxica por imatinib: descripción de dos casos y revisión de la literatura médica , 2007 .

[12]  B. Nilsson,et al.  Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST) , 2007, British Journal of Cancer.

[13]  A. Pariente,et al.  Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. , 2006, European journal of gastroenterology & hepatology.

[14]  M. Ziol,et al.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. , 2003, Ultrasound in medicine & biology.

[15]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[16]  R. Pazdur,et al.  Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. Baccarani,et al.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.

[18]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[19]  J. Doroshow,et al.  Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Granell,et al.  [Imatinib-induced toxic hepatitis: description of two cases and review of the literature]. , 2007, Gastroenterologia y hepatologia.